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The Serum Response Factor (SRF) coactivator myocardin stimulates the transcription of multiple muscle genes during cardiac and smooth
muscle development. Mouse embryos lacking myocardin die during the earliest stages of smooth muscle development and fail to express multiple
smooth muscle marker genes in the embryonic dorsal aorta and other vascular structures. In this study, we used mutant embryonic stem cell lines
to further define the role of myocardin in smooth muscle differentiation and vascular development. Misexpression of myocardin in
undifferentiated muscle stem cells resulted in efficient activation of smooth muscle genes, and weaker activation of genes involved in cardiac and
skeletal muscle differentiation. Remarkably, myocardin/ embryonic stem cell lines differentiated into smooth muscle cells in vitro, although
these cells expressed significantly decreased levels of smooth muscle contractile genes. Moreover, genetically labeled myocardin/ ES cells were
able to contribute to smooth muscle lineages in vivo. These results indicate that while myocardin function is sufficient for activation of SRF-
dependent muscle gene expression in multiple cell types, myocardin-independent mechanism(s) can suffice for expression in some smooth muscle
lineages.
D 2005 Elsevier Inc. All rights reserved.Keywords: Myocardin; Smooth muscle; Stem cells; Differentiation and transcriptionIntroduction
Smooth muscle cells (SMCs) play multiple physiological
roles in the adult organism, providing critical functions in the
cardiovascular, respiratory, genitourinary, and gastrointestinal
systems. The embryonic origins of SMCs reflect this diversity.
The SMCs of the cardiovascular system alone are derived from
three distinct sources from two germ layers: ectodermally-
derived neural crest cells contribute to the SMCs of the outflow
tract and proximal aorta, and mesodermally-derived cells
comprise the SMC layer of the coronary and other vessels
(Hirschi and Majesky, 2004; Hungerford and Little, 1999).0012-1606/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.ydbio.2005.10.014
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E-mail address: eric.olson@utsouthwestern.edu (E.N. Olson).The molecular events that control this diversity of SMC
origin and function largely consist of combinatorial interactions
among several transcriptional regulators (Kumar and Owens,
2003). In particular, Serum Response Factor (SRF), a member
of the MADS (MCM1, Agamous, Deficiens, SRF) family of
transcription factors, has been shown to be a critical regulator
of SMC genes. SRF binds to a cis-regulatory element called a
CArG box (of the consensus CC(A/T)6GG), which is found in
the regulatory regions of many cardiac and skeletal muscle
genes and almost all SM genes (Miano, 2003). SRF activity is
absolutely required in vivo for the development of SMCs
(Miano et al., 2004). The activity of SRF during SMC
differentiation is regulated via interactions among several other
proteins, including GATA-4 and GATA-6 (Oh et al., 2004; Yin
and Herring, 2005), Elk-1 (Wang et al., 2004), histone88 (2005) 502 – 513
www.e
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powerful transcriptional co-activator myocardin (Wang et al.,
2003).
Myocardin was discovered as a coactivator of SRF-
dependent gene expression specifically expressed in cardiac
and SMC lineages during development (Wang et al., 2003) and
was subsequently shown to be sufficient for the misexpression
of CArG-dependent SMC genes in non-muscle cells in several
gain-of-function assays (Chen et al., 2002b; Du et al., 2003;
Wang and Olson, 2004; Wang et al., 2003; Yoshida et al.,
2003). Myocardin is such a strong activator of CArG-
dependent muscle genes that it can induce the expression of
inappropriate CArG-dependent muscle genes in vitro, such as
inducing skeletal and cardiac forms of a-actin when over-
expressed in SMCs (Yoshida et al., 2004), as well as in spinal
cord neurons in vivo (Small et al., 2005).
There are two other members of the myocardin family, the
Myocardin Related Transcription Factors (MRTFs) -A and -B.
Both of these proteins are widely expressed throughout
development, and are likely to be functionally redundant with
myocardin in some tissues. They both co-activate high levels of
CArG-dependent gene transcription in vitro via an association
with SRF (Wang et al., 2002). Depending on the conditions,
MRTF-A is capable of activating 3- to 4-fold higher levels of
expression of several CArG-dependent muscle genes than is
myocardin (Du et al., 2004). Recent work shows that a muscle-
specific signaling mechanism drives MRTF-A and -B into the
nucleus, indicating that MRTF-A and -B almost certainly play
some role in stimulating the expression of CArG-dependent
muscle genes in muscle cells (Kuwahara et al., 2005).
Consistent with its role in activation of SMC gene
expression, knockout mice lacking myocardin die at E10.5,
displaying severe defects in vascular development: the expres-
sion of CArG-dependent muscle genes is absent from the
region where the dorsal aorta normally differentiates, and
mutant yolk sacs appear avascular (Li et al., 2003). This early
lethality precludes detailed analysis of myocardin’s role in
SMC differentiation in other contexts, yet several observations
suggest there must be myocardin-independent mechanisms that
activate SMC genes in tissues other than the embryonic dorsal
aorta. First, the CArG-dependent SMC marker genes SM22 and
a SM actin are both expressed normally in tissues other than
the dorsal aorta in E10.5 myocardin/ embryos, such as the
somites and the heart tube. Second, myocardin is only
expressed in a subset of vascular and visceral SMC types
during embryogenesis. The SMCs of the genitourinary system,
for example, where myocardin is not expressed, must have an
alternate mechanism to drive the expression of CArG-
dependent SMC genes such as SM-MHC and a SM actin
(Wang and Olson, 2004). Recently, murine mesoangioblasts,
developmentally important stem cells associated with the
dorsal aorta, were shown to express multiple SMC genes in
vitro in the absence of detectable expression of myocardin
(Brunelli et al., 2004). Finally, myofibroblasts do not appear to
express myocardin yet can activate a subset of CArG-
dependent SMC genes including those encoding a SM actin
and SM22 (Yoshida and Owens, 2005; Yoshida et al., 2003).In the present study, we used a variety of gain- and loss-of-
function approaches to further investigate the sufficiency and
necessity of myocardin for SMC differentiation. We show that
myocardin functions to activate high levels of SMC genes in
undifferentiated cells: misexpression of myocardin in prolifer-
ating skeletal myoblasts resulted in high levels of smooth
muscle and some cardiac gene expression, while loss of
myocardin function resulted in consistent decreases in SM gene
expression in vitro. In vivo, ES cells null for myocardin were
able to contribute to grossly normal visceral and vascular
smooth muscle tissues. These findings reveal that, although
myocardin is an extraordinarily potent activator of SMC gene
expression, myocardin-independent pathways can drive SMC
differentiation in vivo.
Materials and methods
Transcriptional profiling and cell culture
The human skeletal satellite cell line HSKM5 was derived as described
(Cronin et al., 2004). A derivative of these cells was cultured in growth medium
until infection in serum-free medium with Ad-myocardin or Ad-h-galactosi-
dase. Adenoviruses are described in (Wang et al., 2003). Infected cells were
maintained in growth medium for 48 h, and total RNA was harvested using
TRIzol (Invitrogen) following manufacturer’s protocols. Total RNA was used
as a template for reverse transcription using a T7 promoter-containing poly-dT
primer. cDNA was labeled for oligonucleotide microarray transcriptional
profiling using the Enzo BioArray labeling kit (Enzo Biochem, New York,
NY). Labeled cRNA was then hybridized to the Affymetrix Human Genome
HG-U133A and HG-U133B chips following the manufacturer’s protocols
(Affymetrix, Santa Clara, CA). Array analysis was performed using Microarray
suite 5.0, using user-definable parameters at default settings; MAS reports of
present vs. absent and increased/decreased vs. no change were used at default
confidence intervals and measures of significance. These results were exported
to Microsoft Excel and a Microsoft Access database developed at Academic
Computing Services at the University of Texas Southwestern Medical Center
for detailed classification and sorting of target genes by function according to
Gene Ontology classification. Microarray results were verified for selected
transcripts using TaqMan probes from ABI on an ABI 7000 SDS, normalizing
to 18S rRNA using the delta–delta Ct method according to manufacturer’s
protocols (Applied Biosystems, Foster City, CA).
For prediction and curation of predicted CArG boxes in the promoter
regions of candidate myocardin target genes, weak consensus CArG boxes
deviating from the consensus CCHWDWWWGG by one or fewer nucleotides
were located relative to the predicted start of transcription of one of the
reference sequences listed in Entrez Gene in murine and human genomic
sequence. Evolutionary conservation of some predicted CArG boxes was
ascertained using rVISTA (http://rvista.dcode.org).
All of the transcriptional profiles developed in the course of these studies
will be deposited in the Gene Expression Omnibus (GEO) database at NCBI
and their accession numbers appended to this publication.
Generation of myocardin null ES cells, in vitro differentiation and
analysis of in vitro differentiated cells
Uteri from myocardin/+ mouse (Li et al., 2003) intercrosses were washed
at E3.5 and the resulting blastocysts were plated on a layer of mitotically
inactivated SNL feeder cells in standard ES cell medium including 20% FBS
and LIF. Note that these cells were mixed 129 SvEvTac / C57BL/6. Resulting
ES cell colonies were expanded on feeders in ES cell medium and genotyped.
ES cell line genotype was confirmed using RT-PCR specific for the exon of
myocardin deleted in the knockout allele on RNA from differentiated ES cell
cultures. Male myocardin/ and myocardin+/+ cell lines were differentiated in
vitro according to three different protocols. Cells were differentiated as
embryoid bodies formed in hanging drops of ES cell medium without LIF as
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plating them at high density and removing LIF, following (Weitzer et al., 1995).
In order to obtain high levels of consistent SM differentiation, cells were also
differentiated as embryoid bodies (EBs) in the presence of retinoids and cAMP
as per (Sinha et al., 2004). Cultures were examined microscopically on a daily
basis to score the progress of differentiation. Differentiation cultures were
grown until the indicated time point, then total RNA was harvested using
TRIzol following the manufacturer’s protocols. RNA from at least two cultures
was pooled for each time point. 2 Ag of total RNA was used as a template for
random-primed RT-PCR using SuperScript III (Invitrogen) according to
manufacturer’s protocols. Varying concentrations of this cDNA were used as
template for PCR analysis, from 0.2 AL to 4 AL, depending on the expression
level of the gene. Real time PCR analysis was performed using Taqman probes
in an iCycler (BioRad). Real time PCR probes were of the following sequences:
aSMA forward CGCTGTCAGGAACCCTGAGA, reverse CGAAGCC-
GGCCTTACAGA, probe CAGCACAGCCCTGGTGTGCGAC; SM-MHC
forward TGGACACCATGTCAGGGAAA, reverse ATGGACACAAGTGC-
TAAGCAGTCT, probe AGAACACTAAACGACAGCAGAGCCCAGC; 18S
forward CGGCTACCACATCCAAGGAA, reverse AGCTGGAAT-
TACCGCGGC, probe TGCTGGCACCAGACTTGCCCTC. RT-PCR analysis
using EtBr stained Agarose gels was performed on an iCycler using the
following primer sequences: myocardin exon 8 forward primer: AGACCC-
CAAACCAAAGGTGAAGAAGCTC, myocardin exon 10 reverse: GGAGC-
TTGTGCTGCCAAAGGGGTAGAAG. Other RT-PCR primer sequences were
from (Niu et al., 2005) Immunocytochemistry was performed as per (Sinha
et al., 2004).
Chimeric analysis
Mixed backgroundmyocardin/+ mice were crossed to ROSA26/+ mice in a
pure 129 background (Jackson Labs, Bar Harbor, ME) andmale ES cell lines that
weremyocardin/, ROSA26/+ andmyocardin/+, ROSA26/+were obtained as
described above. These lines were expanded and injected into the inner cell mass
of wild type C57BL/6 blastocysts and implanted into pseudopregnant host dams.
Dams were sacrificed at E12.5 of embryonic development and conceptuses
removed, embryos were freed from amniotic membranes, the chest wall was
punctured to expose the developing aorta to fixative and staining solution, and
embryos were fixed for 1 h on ice in 4% paraformaldehyde in PBS. Embryos
were then rinsed twice in PBS and stained overnight in X-gal staining solution (5
mM ferrocyanide, 5 mM ferricyanide, 2 mM MgCl2, 0.1% NP40, 1 mg/mL X-
gal in dimethylformamide). Embryos were subsequently rinsed twice with PBS
and post-fixed overnight at 4-C in neutral buffered formalin. Embryos were then
rinsed twice with PBS and processed for paraffin-embedding. Paraffin sections
were cut every 10 AM from anterior to the dorsal aorta to posterior to the thoracic
extension of the lungs. E16.5 embryos were harvested, grossly dissected and
fresh frozen in OCT embedding medium, then sectioned into 8 AM sections.
These sections were dried, then fixed in cold acetone for 5 min and processed for
immunohistochemistry or Xgal staining. Adult mice resulting from chimeric ES
cell injections were sacrificed at P28 and the aorta, uterus, heart and liver were
fixed in 4% paraformaldehyde at 4-C for 1 h, then stained for h-galactosidase
activity overnight at 37-C.
Results
Myocardin misexpression in vitro results in the transcriptional
stimulation of multiple types of muscle genes
Because some chromatin states are not permissive for
transcriptional stimulation, we developed a transcriptional
profile of the spectrum of genes activated by myocardin using
skeletal myoblasts, a cell type predicted to have chromatin
structure permissive for activation of muscle genes and to
possess any muscle-specific co-factors required for muscle gene
expression. Additionally, we reasoned that since myocardin is
such a potent stimulator of transcription, the fact that skeletalmuscle cells do not express endogenous myocardin (Chen et al.,
2002b; Wang et al., 2001) would mean that the baseline levels of
myocardin target genes in muscle would be lower than in smooth
or cardiac muscle cells, hence providing a sensitized context in
which to observe the effects of myocardin misexpression.
In comparison to cells in which h-galactosidase was
misexpressed, myocardin altered the expression of more than
four thousand transcripts (Fig. 1A) but only 267 UniGene
clusters were up-regulated more than 5-fold. This latter group
likely includes most or all of the direct targets of myocardin.
The known genes displaying the most dramatic up-regulation
in response to myocardin all have predicted CArG boxes in
their proximal promoter regions or in their first introns (Fig.
1C.) This list includes many of the genes previously shown to
be bona fide targets of myocardin in vivo, with several notable
exceptions. SM22, for example, was only stimulated 4.9-fold in
response to Ad-myocardin, probably because the basal,
myocardin-independent expression of SM22 is high (Table
1), consistent with SM22 being expressed in developing
skeletal muscle cells in a myocardin-independent fashion in
vivo. Similarly, a cardiac and a SM actin, which are also
expressed at appreciable levels in developing skeletal muscle
cells in vivo, were both stimulated in response to myocardin
misexpression, but were expressed at high levels at baseline in
these cells and showed lower fold-changes than might be
predicted (Table 1). Changes in expression of selected cardiac,
smooth and skeletal muscle marker genes were verified by real
time PCR (Table 1). Examination of the 21 known genes which
were down-regulated greater than 10-fold in myoblasts in
response to myocardin showed no muscle-specific genes, nor
any genes previously described as being CArG-dependent (see
complete microarray dataset in GEO), consistent with myo-
cardin functioning primarily as a transcriptional activator.
A hand-curated list of muscle genes sorted by muscle type
where possible shows that myocardin misexpression resulted in
an almost uniformly strong activation of SMC genes, but only
a moderate stimulation of cardiac and skeletal genes. 86% of a
list of canonical SMC genes was stimulated by myocardin,
while only 44% of cardiac genes and 37% of skeletal genes
were. There were also significant differences in the degree to
which myocardin activated each of these categories of genes.
Averaging the fold-change among all the transcripts listed in
each category revealed that myocardin stimulated SMC genes
an average of 47-fold, cardiac genes 9-fold, and skeletal muscle
genes 0.9-fold (Table 1).
Gene Ontology (GO) classification of the subset of
annotated transcripts stimulated greater than 5-fold in response
to myocardin identifies several genes involved in intermediary
metabolism and cytoplasmic signaling cascades as downstream
targets of myocardin, as might be expected for a mesodermal
cell in the process of differentiating into muscle (Fig. 1B).
SRF and SRF co-activators have been implicated in
regulating both muscle genes and cellular growth and prolifer-
ation genes (Selvaraj and Prywes, 2004; Wang et al., 2004). We
analyzed the proportions of muscle genes activated by myo-
cardin in comparison to the proportion of cell growth genes.
Examining all genes increased (by Affymetrix MAS5.0 criteria)
Fig. 1. Transcriptional profiles of a human myoblast cell line infected with adenoviral myocardin. Microarrays compare gene expression profiles of cells infected with
Ad-myocardin and Ad-lacZ, as a control. Hybridization was performed using Affymetrix Human A and B chips, composed of 44860 probes combined, representing
28474 Unigene clusters. (A) Number of probes responding by fold change. (B) Classifications of the 285 known genes stimulated 5-fold or greater in myoblasts,
abstracted from GO annotations; 130 are either novel or are classified as belonging to a classification with fewer than 10 members and are not shown (see
supplemental data). (C) Detailed list of the genes with defined functions that responded greater than 50-fold (highest probe), noting positions of nearby predicted
CArG boxes, although it is not known whether or not most of these CArGs are functional. CArG boxes evolutionarily conserved to mouse are listed in bold.
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than for regulation of cell growth genes: myocardin misexpres-
sion only stimulated 7% (55/797) of genes classified as
regulating cellular proliferation, but 29% (98/334) of genes
classified as regulating muscle development or function.
Myocardin null ES cells differentiate into SMCs with altered
levels of SMC marker gene transcripts
The early lethality of myocardin null embryos precludes
analysis of myocardin’s role in the development of any tissuepast E10.5. Therefore, we generated myocardin null and
control ES cell lines of the same sex and genetic background
from intercrosses of heterozygous myocardin mice and allowed
them to differentiate in vitro as embryoid bodies in hanging
drops, which gives consistent cardiac differentiation, and also
in crowded Fflat_ cultures in the absence of LIF, which provides
differentiation of all three muscle types. Control ES cells do not
express myocardin during normal growth in high serum in the
presence of LIF, but differentiate into myocardin-expressing
cells which are presumably SMC or cardiac precursor cells
(Fig. 2). These cells express myocardin co-factors, including
Table 1
Responses of known muscle genes to myocardin misexpression in myoblasts (highest probe)
Genbank accession
number
Unigene
cluster
number
Gene name Gene
symbol
Ad-myocardin
signal
Ad-hgal
signal
Fold
changea
Real time
PCR fold
change
Average
fold change
for category
Cardiac genes 9.6
NM_005159 Hs.118127 Actin, alpha, cardiac muscle ACTC 25,196 19,852 1.2
NM_001257 Hs.63984 Cadherin 13, H-cadherin (heart) CDH13 680 416 1.4
NM_000718 Hs.69949 Calcium channel, voltage-dependent,
L type, alpha 1B subunit
CACNA1B 8 7 1.4
NM_000719 Hs.89925 Calcium channel, voltage-dependent,
L type, alpha 1C subunit
CACNA1C 67 45 1.4
NM_000720 Hs.23838 Calcium channel, voltage-dependent,
L type, alpha 1D subunit
CACNA1D 135 59 2.1
AI391509 Hs.1294 Calcium channel, voltage-dependent,
L type, alpha 1S subunit
CACNA1S 216 218 1.1
NM_001232 Hs.57975 Calsequestrin 2 (cardiac muscle) CASQ2 5442 2455 2.1
NM_014391 Hs.355934 Cardiac ankyrin repeat protein CARP 282 117 2.5
AI041520 Hs.49881 Fatty acid binding protein 3,
muscle and heart
FABP3 276 91 2.6
NM_001450 Hs.8302 Four and a half LIM domains 2 FHL2 2107 1070 2.1
NM_000165 Hs.74471 Gap junction protein, alpha 1,
43 kDa (connexin 43)
GJA1 100 74 2.0
NM_005497 Hs.377116 Gap junction protein, alpha 7,
45 kDa (connexin 45)
GJA7 185 94 1.6
NM_006037 Hs.91400 Histone deacetylase 4 HDAC4 68 89 2.0
NM_005474 Hs.9028 Histone deacetylase 5 HDAC5 336 788 2.5
NM_014707 Hs.116753 Histone deacetylase 9 HDAC9 113 51 2.1
NM_000256 Hs.258742 Myosin binding protein C, cardiac MYBPC3 51 64 1.4
D00943 Hs.278432 Myosin, heavy polypeptide 6,
cardiac muscle, alpha
MYH6 1710 174 12.1 17.2
NM_000257 Hs.929 Myosin, heavy polypeptide 7,
cardiac muscle, beta
MYH7 2102 741 2.0
AK000947 Hs.154788 Myosin, heavy polypeptide 7B,
cardiac muscle, beta
MYH7B 7 8 1.1 undet
AF020768 Hs.75535 Myosin, light polypeptide 2,
regulatory, cardiac, slow
MYL2 1995 1244 1.9
M30262 Hs.75640 Natriuretic peptide precursor A NPPA 747 119 4.3
NM_002509 Hs.355454 NK2 transcription factor related, locus 2 NKX2-2 348 40 8.6
NM_002521 Hs.219140 Natriuretic peptide precursor B NPPB 3533 32 111.4 >28,000
M60411 Hs.85050 Phospholamban PLN 1079 7 119.4
BE968750 Hs.90821 Ryanodine receptor 2 (cardiac) RYR2 4 7 3.7
NM_000335 Hs.169331 Sodium channel, voltage-gated, type V,
alpha polypeptide
SCN5A 167 220 1.4
U80987 Hs.50947 T-box 5 TBX5 61 15 4.9
NM_000363 Hs.351582 Troponin I, cardiac TNNI3 98 115 1.0
X79857 Hs.296865 Troponin T2, cardiac TNNT2 4535 3481 1.3
Smooth muscle genes 47.4
NM_001613 Hs.195851 Actin, alpha 2, smooth muscle, aorta ACTA2 27,287 5307 4.6
NM_001615 Hs.378774 Actin, gamma 2, smooth muscle, enteric ACTG2 18,591 227 59.7
D90453 Hs.325474 Caldesmon 1 CALD1 1585 478 3.5
NM_001299 Hs.21223 Calponin 1, basic, smooth muscle CNN1 770 26 21.1 152
NM_022870 Hs.78344 Myosin, heavy polypeptide 11,
smooth muscle
MYH11 5280 14 238.9 5042
NM_005876 Hs.21639 Nuclear protein, marker for differentiated
aortic smooth muscle
APEG1 314 172 1.9
NM_006932 Hs.149098 Smoothelin SMTN 671 220 2.1 10
Skeletal muscle genes 0.9
NM_001100 Hs.1288 Actin, alpha 1, skeletal muscle ACTA1 22,893 8139 2.5
NM_001231 Hs.60708 Calsequestrin 1 (fast-twitch,
skeletal muscle)
CASQ1 404 69 4.9
NM_000083 Hs.121483 Chloride channel 1, skeletal muscle CLCN1 62 42 1.2
NM_001824 Hs.334347 Creatine kinase, muscle CKM 4418 1511 2.6
NM_005592 Hs.156465 Muscle, skeletal, receptor
tyrosine kinase
MUSK 88 166 2.5
NM_002479 Hs.2830 Myogenin (myogenic factor 4) MYOG 269 1181 3.2 4
NM_004533 Hs.85937 Myosin binding protein C, fast type MYBPC2 20 4 2.1
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Table 1 (continued)
Genbank accession
number
Unigene
cluster
number
Gene name Gene
symbol
Ad-myocardin
signal
Ad-hgal
signal
Fold
changea
Real time
PCR fold
change
Average
fold change
for category
Skeletal muscle genes 0.9
BF593509 Hs.169849 Myosin binding protein C,
slow type
MYBPC1 741 161 4.3
NM_005963 Hs.231581 Myosin, heavy polypeptide 1,
skeletal muscle, adult
MYH1 19 46 2.1
NM_003802 Hs.278488 Myosin, heavy polypeptide 13,
skeletal muscle
MYH13 111 79 1.3
NM_017534 Hs.931 Myosin, heavy polypeptide 2,
skeletal muscle, adult
MYH2 260 190 1.7
NM_002470 Hs.173084 Myosin, heavy polypeptide 3,
skeletal muscle, embryonic
MYH3 6488 3082 1.9
NM_017533 Hs.272207 Myosin, heavy polypeptide 4,
skeletal muscle
MYH4 12 7 1.2
NM_002472 Hs.113973 Myosin, heavy polypeptide 8,
skeletal muscle, perinatal
MYH8 482 594 1.2
M20643 Hs.158295 Myosin, light polypeptide 1,
alkali; skeletal, fast
MYL1 9538 3209 3.0
NM_003282 Hs.83760 Troponin I, skeletal, fast TNNI2 387 450 1.3
NM_003281 Hs.84673 Troponin I, skeletal, slow TNNI1 5170 6441 1.2
AJ011712 Hs.73980 Troponin T1, skeletal, slow TNNT1 4854 5932 1.1
NM_006757 Hs.73454 Troponin T3, skeletal, fast TNNT3 572 560 1.2
General muscle genes
AV700724 Hs.243987 GATA binding protein 4 GATA4 5 16 1.1
D87811 Hs.50924 GATA binding protein 6 GATA6 14 3 2.0
NM_005587 Hs.182280 Myocyte enhancer factor 2A MEF2A 215 161 1.4
NM_005919 Hs.78881 Myocyte enhancer factor 2B MEF2B 44 51 1.4
N22468 Hs.78995 Myocyte enhancer factor 2C MEF2C 830 1732 2.1
AL530331 Hs.77955 Myocyte enhancer factor 2D MEF2D 108 52 1.6
NM_005368 Hs.118836 Myoglobin MB 169 179 1.1
NM_003186 Hs.433399 Transgelin TAGLN 23,462 4927 4.9
BF825274 Hs.434384 Titin TTN 2397 2076 1.1
NM_003673 Hs.343603 Titin-cap (telethonin) TCAP 142 114 1.1
NM_006063 Hs.50550 Sarcomeric muscle protein SARCOSIN 1422 2817 2.1
AI089932 Hs.179838 Phosphofructokinase, muscle PFKM 484 246 2.6
NM_002637 Hs.2393 Phosphorylase kinase, alpha 1
(muscle)
PHKA1 177 71 1.9
NM_006213 Hs.512612 Phosphorylase kinase, gamma 1
(muscle)
PHKG1 78 44 1.7
a Fold change calculated using MAS5.0 algorithm.
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differentiation (Fig. 2).
Analyzing the expression of marker genes for cardiac and SM
differentiation by RT-PCR showed no consistent deficit in
cardiac or SM differentiation in myocardin null cells: a SM
actin, a cardiac actin and SM-MHC were all expressed at
comparable times during differentiation experiments between
myocardin null and control cell lines, although SM-MHC
expression was never high in either protocol (Fig. 2). Compar-
ison of the transcriptional profiles of 20 day flat differentiated
myocardin/ and myocardin+/+ ES cell cultures generated
using Affymetrix mouse genome 2.0 microarrays revealed that
no known CArG-dependent transcripts were significantly
altered in the absence of myocardin (data not shown).
Spontaneously and rhythmically contracting foci were
consistently observed in cells of either genotype under either
differentiation protocol after 6 days of differentiation. The cells
that contribute to these foci have previously been shown to besimilar to cardiac cells, in that their contractions are communi-
cated through gap junctions (Boheler et al., 2002). Thus,
myocardin does not appear to be required in developing
mammalian cardiomyocytes for the elaboration of coordinated
contractile activity. These foci were not observed to decrease
contractile activity during further differentiation in cells of either
genotype.
In order to obtain consistent SMC differentiation of ES cells
in vitro, we employed a modified EB differentiation protocol in
the presence of retinoids and cAMP (Sinha et al., 2004). The
myocardin null SMCs obtained using this protocol appeared to
be phenotypically normal, expressing normal levels of SMC
contractile proteins at similar levels as control ES cells as
assayed by immunocytochemistry (Fig. 3). The levels of the
transcripts encoding these proteins, on the other hand, were
consistently dysregulated in myocardin null ES cell cultures. At
15 days of differentiation, myocardin null ES cell cultures
expressed increased levels of these transcripts (Fig. 4). After 28
Fig. 3. Myocardin null and control ES cells differentiate in vitro into SMCs
Myocardin null and control ES cells were differentiated using a modified
embryoid body differentiation protocol that enriches for smooth muscle cel
differentiation. Differentiation cultures were fixed at 28 days and stained with
antibodies against the SMC marker proteins smooth muscle myosin heavy
chain (SM-MHC) and smooth muscle a actin (a-SMA) (red) and counter
stained with DAPI (blue).
Fig. 2. Myocardin null and control ES cells express MRTF-A and related
accessory factors when differentiating in vitro. Myocardin null and control ES
cells derived from blastocysts from myocardin/+ intercrosses were differen-
tiated in vitro as embryoid bodies in hanging drops in the absence of LIF (upper
panels), or as confluent ES cell cultures without LIF (flat differentiation) for the
specified number of days, then total RNA was harvested and analyzed for the
expression of the indicated transcripts by RT-PCR. ‘‘d0’’ refers to cells before
differentiation, ‘‘a-SKA’’ refers to skeletal a actin, ‘‘a-SMA’’ refers to smooth
muscle a actin and ‘‘a-CA’’ refers to cardiac a actin.
G.C.T. Pipes et al. / Developmental Biology 288 (2005) 502–513508days of differentiation, there was a consistent 2-fold decrease in
the levels of these transcripts. Thus, co-activation by myocar-
din is not required for the expression of these CArG-dependent
SMC structural genes under all conditions, but in the absence
of myocardin, levels of these transcripts are untimely and
uncoordinated compared to differentiation of wild type cells.
Chimeric analysis of myocardin null ES cells
To further assess the potential role of myocardin in smooth
muscle differentiation in vivo, we derived male h-galactosi-
dase+ myocardin/+ and myocardin/ ES cell lines from
intercrosses between myocardin/+ mice harboring the
ROSA26 gene trap, which expresses h-galactosidase in all
cell types (Zambrowicz et al., 1997). Injecting myocardin/+ or
myocardin/ ES cells into the inner cell mass of wild type
host blastocysts yields conceptuses with wild type trophoblast-
derived tissues, while the embryonic vasculature is composed
of a mixture of wild type and mutant cells. Thus, our chimeric
analysis makes it possible to address whether myocardin isrequired cell-autonomously in the embryo only; previously, we
described potentially lethal defects in both the embryonic and
extraembryonic vasculature of myocardin/ embryos (Li et
al., 2003).
Staining of chimeric embryos for h-galactosidase activity
showed that control heterozygous ES cells were capable of
contributing to all embryonic tissues examined (Fig. 5A and
data not shown). Remarkably, examination of myocardin/,
ROSA26/+ ES cell chimeras also showed no specific exclusion
of myocardin/ ES cells from SMC lineages at E12.5. In
particular, Fig. 5B shows a developing aorta composed entirely
of h-galactosidase-expressing myocardin null cells, with an
intact endothelial cell layer and a surrounding thick group of
cells, indicating that developing SMCs populated the endothe-
lial tube normally. Likewise, myocardin/, ROSA26/+ cells
could be observed in the SMC layer of the major vessels in
older embryos (Fig. 5C) and in adults (Figs. 5D–E).
Immunohistochemical double-labeling h-galactosidase pro-
tein and a-SM actin showed that, as for the in vitro-
differentiated myocardin/ ES cells, in vivo differentiated
myocardin/, ROSA26/+ ES cells were capable of expressing
a component of the SMC contractile apparatus (Fig. 6).
Discussion
In this study, we used loss-of-function and gain-of-
function approaches in stem cells to analyze the role that
myocardin plays in controlling the SMC transcriptosome
and vascular differentiation. Transcriptional profiling of
undifferentiated cells misexpressing myocardin showed that
the transcriptional consequences of myocardin activity are
largely confined to SMC and cardiac genes. Analyzing the
endogenous levels of CArG-dependent SMC-specific tran-
scripts in differentiating myocardin/ ES cell lines showed.
l
-
Fig. 4. Myocardin null ES cells differentiated in vitro as embryoid bodies express altered levels of SMC marker genes. (A) Myocardin expression normalized to 18S
rRNA levels, assayed by real time PCR after 15 days of differentiation and 28 days of differentiation. Myocardin expression increases during SMC-biased
differentiation in myocardin+/+ control cells and is absent in myocardin/ cells. (B) SM-MHC expression normalized to 18S rRNA levels in the same samples as in
panel A. SM-MHC transcript levels were consistently increased in myocardin null cells compared to control cells at day 15, but decreased at day 28. (C) a smooth
muscle actin transcript levels normalized to 18S rRNA in the same samples as in panel A. (D) SM22 transcript levels normalized to 18S rRNA during SM-biased EB
differentiation in myocardin null and control ES cell cultures.
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of SRF-dependent SMC genes, although transcripts encod-
ing three critical SMC genes, a-SM actin, SM-MHC and
SM22, were decreased in the absence of myocardin.
Furthermore, we performed chimeric analysis in order to
bypass the early lethality observed in myocardin/
embryos, demonstrating that embryonic myocardin expres-
sion is not required cell-autonomously for grossly normal
SMC differentiation in vivo.
Myocardin’s unique role in aortic development
Extensive work shows that many muscle genes and almost
all SMC genes are dependent on CArG boxes in their proximal
promoter regions for expression (Miano, 2003). Deleting SRF
in smooth, skeletal and cardiac muscle cells leads to a lethal
diminution in the levels of expression of CArG-dependent
muscle structural genes (Li et al., 2005; Miano et al., 2004; Niu
et al., 2005; Parlakian et al., 2004). Transcriptional stimulation
by SRF is co-activated by members of the myocardin family of
transcription factors, composed of myocardin, MRTF-A and
MRTF-B, each of which is capable of driving extremely high
levels of expression of CArG-dependent muscle genes (Wanget al., 2002). This activity is an absolute requirement for proper
expression of CArG-dependent muscle genes: dominant
negative forms of myocardin and MRTF-A result in dramatic
and lethal decreases in the expression of muscle structural and
contractile genes (Li et al., 2005; Selvaraj and Prywes, 2003;
Wang et al., 2001; Yoshida et al., 2003).
A homozygous single-gene mutation in myocardin is lethal
during the earliest stage of SMC development in vivo, and
embryos lacking myocardin show no expression of the most
terminal SMC differentiation marker, SM-MHC (Li et al.,
2003). However, we show that myocardin/ ES cells can
successfully populate the embryonic aorta during late embryo-
genesis and even adulthood. How can these findings be
reconciled with our prior study showing that myocardin is
essential for SMC differentiation during embryogenesis?
There are several possible explanations for why we recovered
myocardin null SMCs. Myocardin may be required cell-
autonomously for SMC development in the dorsal aorta, but
that requirement could be transient and satisfied at E10.5 or
before by a small number of wild type cells which we cannot
detect at later stages. It may also be that the requirement for
myocardin in vascular SMC differentiation is non cell-autono-
mous—e.g., a small number of myocardin+/+ host cells could
Fig. 5. ROSA26-labeled myocardin null ES cells differentiate into vascular SMC in vivo. Heterozygous and null myocardin ES cells genetically labeled h-
galactosidase+ with ROSA26 were injected into wild type blastocysts, allowed to develop to various ages, then harvested and stained for h-galactosidase activity.
Panel A is from a control injection of heterozygous cells in an E12.5 embryo, showing contribution of ES cells to multiple tissue types. Panels B–E are from
myocardin/, ROSA26/+ ES cells injected into wild type host blastocysts and depict grossly normal endothelial and developing SMC layers in major arteries. (B)
Thoracic aorta from an E12.5 chimeric embryo showing contribution of myocardin null cells to the SMC layer. (C) Subclavian artery from an E16.5 chimeric embryo
showing contribution of myocardin null cells to the SMC layer. (D) Thoracic aorta from a P28 adult showing contribution of myocardin null cells. (E) Cross-section
of an identically-prepared aorta as in panel D, showing that blue, myocardin null cells are present in the inner SMC layer. Scale bars = 100 Am. pl—pleural cavity;
Atr—Atrium; ln—lung.
G.C.T. Pipes et al. / Developmental Biology 288 (2005) 502–513510secrete a factor required for SMC differentiation. In support of
this hypothesis, we note that aortas from high percentage
myocardin/, ROSA26/+ adult mice always harbor a signifi-
cant proportion of wild type cells (see Fig. 5D). Alternatively, we
favor the possibility that myocardin activity is not required in the
dorsal aorta for embryonic viability, but instead is required in
some extraembryonic vascular tissue(s).
Chimeric analyses, including tetraploid rescue, morula
aggregation and the straightforward ES cell injections we
present here, cannot conclusively determine which tissue
requires myocardin activity for embryonic viability. Each of
these manipulations can result in chimeric extraembryonic
tissues (Beddington and Robertson, 1989), leaving open theFig. 6. Normal expression of a-smooth muscle actin protein by myocardin/ SM
galactosidase+ with ROSA26 were injected into wild type blastocysts and sacrificed
green (marking myocardin null cells) and anti-a SM actin in red. This section, just
near the junction between two major vessels expressing a SM actin.possibility that the requirement for myocardin for viability is
non-cell autonomous. The current study only asks whether or
not myocardin is required cell autonomously for SMC
differentiation, not where myocardin is required for embryonic
viability. Proof of which tissue requires myocardin activity for
embryonic viability awaits the tissue-specific deletion of
myocardin from subsets of extraembryonic or embryonic
vascular tissues using a floxed allele of myocardin.
Assuming that myocardin is required cell-autonomously for
vascular SMC differentiation in the dorsal aorta, why are
MRTF-A or -B, which are broadly expressed and capable of
driving high levels of SMC gene expression in vitro, unable to
compensate for the lack of myocardin activity in myocardinC in vivo. Heterozygous and null myocardin ES cells genetically labeled h-
and cryosectioned at E16.5. Sections were labeled with anti-h-galactosidase in
rostral to the aortic arch, depicts multiple myocardin null ES cell-derived SMC
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sequestered in the cytoplasm and rendered transcriptionally
inactive by actin (Miralles et al., 2003). In differentiating
striated muscle cells, a protein called STARS drives MRTF-A
and -B into the nucleus, preventing the high levels of muscle
actins required for muscle contraction from repressing MRTF-
A and -B’s transactivation of CArG-dependent muscle target
genes (Kuwahara et al., 2005). Any tissue which lacks STARS
protein but requires the activity of a myocardin family member
for proper expression of CArG-dependent genes would then be
predicted to have defects in the expression of contractile
proteins in myocardin mutants. It may be that expression of a
SM actin or the actin rearrangements required for migration to
the endothelial tube result in the sequestration of MRTF-A and
-B in the cytoplasm of these cells, revealing a tissue-specific
requirement for myocardin. Alternatively, MRTF-A and/or B
may not compensate for the absence of myocardin in certain
SMC tissues simply due to differences in transcriptional
regulatory controls between these three genes, and their
responsiveness to environmental cues present within develo-
ping SMC tissues.
Co-activators of SRF and muscle gene expression
SRF is required for the expression of CArG-dependent SMC
genes under all conditions examined (Weinhold et al., 2000),
but the current results indicate that this is not true for
myocardin. Myocardin null cells are capable of differentiating
into SM-MHC+ SMCs, a novel finding that we could not make
previously due to the early lethality of myocardin null
embryos. In vitro differentiated myocardin null ES cells
express reduced levels of SMC transcripts, indicating that,
although myocardin-independent mechanisms can provide a
basal level of SM gene expression, myocardin is required for
the high levels of expression normally present in a differen-
tiated SMC.
In addition to being required for activation of muscle genes,
SRF also activates genes which regulate cellular proliferation,
including immediate early genes (Buchwalter et al., 2004). Our
results highlight a significant preference for activation of
muscle genes by myocardin, consistent with previous work
showing that myocardin promotes differentiation of muscle
cells (Liu et al., 2005a,b; Wang et al., 2004). There are several
possible explanations for how myocardin achieves this
selectivity. Previous work shows that the activation by
myocardin or MRTFs of many SRF targets is antagonized
by ternary complex factor (TCF) binding at sites adjacent to
the SRE (Selvaraj and Prywes, 2004; Wang et al., 2004). It is
likely that such a mechanism is at work here, although efforts
to connect every target gene’s responsiveness to a particular
set of cis-regulatory elements have been complicated by distal
positioning of enhancer elements. Additionally, many other
transcription factors have been shown to repress SRF
activation at a subset of SRF target gene loci, including
GATA factors (Oh et al., 2004; Yin and Herring, 2005), Elk-1
(Wang et al., 2004), FHL2 (Philippar et al., 2004) and HOP
(Chen et al., 2002a; Shin et al., 2002). Myocardin most likelyinteracts with a transcriptional regulator that the MRTFs do not
in order to selectively co-activate CArG-dependent muscle
target genes.
The transcription of several genes encoding cardiac
structural proteins and proteins required for coordinated
electrical activity, such as those encoding a cardiac actin
and the sodium/potassium exchanger, is also CArG-dependent
(Belaguli et al., 2000; Cheng et al., 1999). Although
myocardin coordinates and regulates the expression of
multiple CArG-dependent cardiac genes, it was previously
found that misexpression of myocardin was not sufficient to
induce beating or cardiac-like coordinated contraction in
Xenopus animal cap assays (Small et al., 2005). Consistent
with this result, our experiments show that the loss of
myocardin does not affect development of the beating
phenotype in mammalian ES cells in vitro. Therefore, the
CArG-dependency of these terminal differentiation markers of
cardiac cells is either sufficiently fulfilled by SRF alone, or
another SRF cofactor is capable of coactivating their
expression to levels sufficient for the elaboration of junc-
tioned, rhythmically contracting muscle tissue in vitro.
Taken together, our results indicate that myocardin is a
potent effector of the SMC transcriptional program, and is
required for normal expression of SMC transcripts during
differentiation. In the absence of myocardin, SMC differentia-
tion appears overtly normal and is sufficient for embryonic
development (although possibly not extra-embryonic develop-
ment) in vivo, but careful examination of SMC genes reveals
deficiencies in the levels of these genes in vitro. It is likely that
MRTF-A and -B can compensate for the lack of myocardin
function in most contexts. A remaining question is whether co-
activation of SRF by any myocardin family member is required
for CArG-dependent SMC gene expression at all. That is, in the
absence of myocardin, MRTF-A and MRTF-B, is the expres-
sion of CArG-dependent contractile genes absent? Answering
this requires the analysis of double- and triple mutant
combinations of myocardin, MRTF-A and -B, and possibly in
vitro differentiation of cells derived from these mutants.
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